| Dr Stavros Nicholas Maltezos, MD | |
|
3825 Highland Ave, Tower 1, Suite 5m, Downers Grove, IL 60515-1552 | |
| (630) 725-9890 | |
| (630) 725-0988 |
| Full Name | Dr Stavros Nicholas Maltezos |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 3825 Highland Ave, Downers Grove, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902987076 | NPI | - | NPPES |
| 0001617783 | Other | IL | BLUE SHIELD OF ILLINOIS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | (Illinois) | Primary |
| Entity Name | Mount Sinai Community Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376715896 PECOS PAC ID: 5991600405 Enrollment ID: O20040202001032 |
News Archive
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis-;deposits of cholesterol, fats and other substances that create plaque, clog arteries and promote heart attacks and stroke. The findings could lead to improved therapies for atherosclerosis, a leading cause of death worldwide.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
In the study, a team of researchers led by Veridex, LLC, a Johnson & Johnson company, used gene expression profiling to identify the new marker – a 23-gene signature – which may predict disease recurrence in patients initially diagnosed with Dukes' B colon cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stavros Nicholas Maltezos, MD Dept 2299 Paysphere Circle, Chicago, IL 60674 Ph: (630) 725-9890 | Dr Stavros Nicholas Maltezos, MD 3825 Highland Ave, Tower 1, Suite 5m, Downers Grove, IL 60515-1552 Ph: (630) 725-9890 |
News Archive
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis-;deposits of cholesterol, fats and other substances that create plaque, clog arteries and promote heart attacks and stroke. The findings could lead to improved therapies for atherosclerosis, a leading cause of death worldwide.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
In the study, a team of researchers led by Veridex, LLC, a Johnson & Johnson company, used gene expression profiling to identify the new marker – a 23-gene signature – which may predict disease recurrence in patients initially diagnosed with Dukes' B colon cancer.
› Verified 2 days ago
Egon Mr Doppenberg, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3551 Highland Ave, Downers Grove, IL 60515 Phone: 844-376-3876 Fax: 630-929-0633 | |
Dr. Raed Fuad Abusuwwa, D.O. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3551 Highland Avenue, Suite 200a, Downers Grove, IL 60515 Phone: 844-376-3876 Fax: 630-929-0633 |